Treatment Approaches Differ by Age Group in Extremity Soft Tissue Sarcoma
Young adults were more likely to receive chemotherapy.
Sarcoma
Triplet Deemed New Standard Care for Relapsed or Refractory Rhabdomyosarcoma
Adding temozolomide to vincristine and irinotecan improved survival.
CMB305 Vaccine Demonstrates Activity But Doesn’t Improve Survival in Soft-Tissue Sarcomas
CMB305 increased antibody responses and NY-ESO-1-specific T-cell responses.
Nanoparticle Albumin-Bound mTOR Inhibitor Gets Priority Review for Ultra-Rare Sarcoma
Nab-sirolimus is an mTOR inhibitor bound to human albumin.
Expanding HDR Brachytherapy Program at a Rural Cancer Center to Include Soft Tissue Sarcoma
A facility in northwest Montana shares its experiences with developing a brachytherapy service and expanding it to include treatment of soft tissue sarcoma.
Radiomic, Clinical Features Predicted Sarcoma Response to Radiation
Radioresistant sarcoma may require treatment intensification.
Radiation for Abdominal, Pelvic Cancers Ups Secondary Sarcoma Risk
Compared with patients who undergo surgery alone for abdominal or pelvic cancers, those who receive radiation and chemotherapy are at elevated risk for secondary sarcomas.
Few High-Grade Soft Tissue Sarcoma Patients Receive Chemo
Percentage of STS patients receiving chemo driven by factors such as tumor size, income, facility type.
Addition of Pazopanib to Neoadjuvant Chemo Found Highly Active in Adult, Pediatric Sarcoma
The study is a collaboration of pediatric, adult cooperative groups.
Histology-Tailored Neoadjuvant Chemotherapy Produces Limited Results in Multinational Study on High-Risk Soft Tissue Sarcoma
Histology-tailored neoadjuvant chemotherapy failed to show superiority compared with standard neoadjuvant chemotherapy in patients with high-risk STS.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Sarcoma
Loading... 
Loading...